Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from $49, following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO: